Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Irak4. fázis

Exploring the Efficacy, Safety of a Modified Starting Dosage of Avatrombopag in Immune Throbocytopenia (ITP) - a Pilot Study

A legfontosabb adatok

Ki végzi
Al-Mustansiriyah University
Hol
Baghdad (Irak)A helyszín megnézése
Azonosító
Állapot
Toboroz
Fázis
4. fázis
Résztvevők
25 fő, tervezett
Kezdés
2025. jún. 8.
Várható befejezés
2027. júl. 8.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Avatrombopag 20 mg Oral Tablet
A regiszteradat frissítve
2025. augusztus 21.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with primary ITP, a low platelet condition, who need a second-line treatment. They will take avatrombopag at a lower starting dose for up to 24 weeks.

Életkor
18 years or older
Nem
All sexes
A betegség stádiuma
Primary ITP with a platelet count below 30 x109/L, measured within two weeks before joining. The doctor must judge that a second-line treatment to raise platelets is needed.
Korábbi kezelés
Steroids did not work, or ITP came back, after at least one course of dexamethasone (20-40 mg daily for 4 days) or prednisone/prednisolone (1 mg/kg for at least two weeks). Shorter or lower courses count if stopped or changed because of side effects. People treated before with a TPO-RA cannot join.
Biomarker vagy leletérték
Platelet count below 30 x109/L

A részvétel fő kizáró okai

  • Pregnancy or breastfeeding
  • Active serious bleeding or high risk of bleeding
  • ITP caused by another disease, such as lymphoma, CLL, lupus, antiphospholipid syndrome, CVID or HIV
  • Autoimmune hemolytic anemia or Evans syndrome
  • Active cancer, except some listed minor or early conditions

A regiszter feltételei, szó szerint

Mind a 13 feltétel megnézéseKevesebb

Ki vehet részt

  • Male or female aged ≥18 years
  • Diagnosis of primary ITP and having a platelet count of < 30 x109/L measured within two weeks prior to inclusion with failure to achieve response or relapse after at least one cycle of dexamethasone (20-40 mg daily for 4 days) or prednisone /prednisolone (1 mg/kg for at least two weeks). Shorter courses or lower doses are allowed if discontinued or modified due to side effects
  • Clinical need for second (subsequent) line treatment with a platelet elevating therapy assessed by the physician in charge
  • Signed and dated written informed consent

Ki nem vehet részt

  • Previous treatment with TPO-RA
  • Females of child-bearing potential refusing to follow effective contraceptive methods (as described in SmPC) during treatment with Avatrombopag
  • Concomitant autoimmune hemolytic anemia, Evans syndrome
  • Patients with active serious bleeding or at high risk of bleeding as judged by physician in charge
  • Secondary ITP defined as ITP secondary to lymphoma or chronic lymphocytic leukemia; ITP secondary to the following autoimmune disorders Systemic Lupus Erythematosus or Antiphospholipid Syndrome; ITP secondary to Common Variable Immune Deficiency; ITP secondary to the following viral infections eg Human Immunodeficiency Virus
  • Presence of any serious comorbidity where the condition may worsen the study drugs
  • Presence of active malignancy unless deemed cured by adequate treatment. Participants with the following neoplastic conditions can be included:; Monoclonal gammopathy of undetermined significance (MGUS) or monoclonal B lymphocytosis of undetermined significance (MBUS); Basal/squamous cell carcinoma of the skin; Carcinoma in situ of the cervix; Carcinoma in situ of the breast; Incidental histological finding of prostate cancer (TNM stage T1a or T1b)
  • Patients with history of poor compliance or history of alcohol/drug abuse or excessive alcohol beverage consumption that would interfere with the ability to comply with the study protocol, or current or past psychiatric disease that might interfere with the ability to comply with the study protocol or give informed consent; -
  • Pregnancy or lactation

Helyszínek itt: Irak

  • hematology center / Medical CityBaghdad, IrakContact: Alaa Alwan, MDRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a single-center, open label pilot trial where patients with primary ITP who require second line treatment will be offered avatrombopag at a reduced starting dose, adjusted thereafter according to the response and continued for up to 24 weeks. The study aims to acquire experience on use of avatrombopag and explore the efficacy and safety of lower starting dose of avatrombopag

A vizsgálat csoportja

  • AvatrombopagA vizsgált kezelés

    Description: Patients will start on avatrombopag 20 mg every other day for a week then the dose will be readjusted according to the platelet count.

    Kezelés: Avatrombopag 20 mg Oral Tablet

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
A regiszteradat frissítve
2025. augusztus 21.